FDA
-
-
-
-
-
-
-
Celcuity's Revtorpyk added to NCCN breast cancer guidelines
-
-
-
-
-
-
-
Celcuity prices $500 million convertible notes offering
-
-
-
-
-
-
-
Celcuity Inc (CELC) PT Raised to $185 at H.C. Wainwright
-
-
-
-
-
-
-
Celcuity publishes breast cancer trial results in medical journal
-
-
-
-
-
-
-
Celcuity reports updated results from breast cancer trial
-
-
-
-
-
-
-
Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance
-
-
-
-
-
-
-
Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
-
330,180 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

